Acid β‐glucosidase (GCase), the enzyme deficient in Gaucher disease (GD), is transported to lysosomes by the lysosomal integral membrane protein (LIMP)‐2. In humans, LIMP‐2 deficiency leads to action myoclonus‐renal failure (AMRF) syndrome. GD and AMRF syndrome share some clinical features. However, (hey are different from clinical and biochemical points of view, suggesting that the role of LLMP‐2 in the targeting of GCase would be different in different tissues. Besides, the role of LLMP‐2 in the uptake and trafficking of the human recombinant (hr) GCase used in the treatment of GD is unknown. Thus, we compared GCase activity and intracellular localization in immortalized lymphocytes, fibroblasts, and a neuronal model derived from multi‐potent adult stem cells, from a patient with AMRF syndrome, patients with GD, and control subjects. In fibroblasts and neuronlike cells, GCase targeting to the lysosomes is completely dependent on LLMP‐2, whereas in blood cells, GCase is partially targeted to lysosomes by a LLMP‐2‐independent mechanism. Although hrGCase cellular uptake is independent of LLMP‐2, its trafficking to the lysosomes is mediated by (his receptor. These data provide new insights into the mechanisms involved in the intracellular trafficking of GCase and in the pathogeneses of GD and AMRF syndrome.—Malini, E., Zampieri, S., Deganuto, M., Romanello, M., Sechi, A., Bembi, B., Dardis, A Role of LIMP‐2 in the intracellular trafficking of β‐glucosidase in different human cellular models. FASEB J. 29, 3839‐3852 (2015). http://www.fasebj.org